Phosphatase and Tensin Gene Associated with Features of Aggressive Prostate Cancer
Introduction The current study examined the clinical impacts of phosphatase and tensin (PTEN) expression in prostate cancer (PCa) using immunohistochemistry. Methods 50 patients with mean age of 66.4±7.3 years who had undergone prostatectomy surgery with the diagnosis of PCa, were enrolled in the...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Urology Research Center
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e0c7b77008084beb910840814657d8ff |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Introduction
The current study examined the clinical impacts of phosphatase and tensin (PTEN) expression in prostate cancer (PCa) using immunohistochemistry.
Methods
50 patients with mean age of 66.4±7.3 years who had undergone prostatectomy surgery with the diagnosis of PCa, were enrolled in the study. We collected 50 paraffin blocks from the malignant part and 50 paraffin blocks from the healthy part of each patient’s prostate. We considered malignant and healthy parts as the case and the control, respectively. Clinical and pathological information of the patients were gathered and their associations with PTEN status were assessed using odds ratios (ORs) analysis.
Results
The significant associations between tumor stage, perivascular invasion, perineural invasion, marginal involvement, extraprostatic extension, and biochemical recurrence (as assed by post-surgical prostate-specific antigen (PSA)) and PTEN expression were detected. For patients negative for PTEN, the odds ratio of the higher stage, perivascular invasion, perineural invasion, marginal involvement, and extraprostatic extension in comparison to patients positive for PTEN were estimated 7.5 (95%CI: 2.01,27.86), (95%CI: 1.65-25.57), 7.8 (95%CI:1.54-40.09), 9.78 (95%CI:2.33-41.08), and 4.84 (95%CI:1.07-21.84), respectively. Concerning biochemical recurrence, ORs was calculated 0.30 (95%CI:0.09-1.02) for PTEN positive patients compare to PTEN negative patients.
Conclusions
Since PTEN loss was associated with features of aggressive PCa, it can be concluded that loss of PTEN would lead to more aggressive PCa and thereby, lower clinical outcomes. |
|---|